One-Shot gene therapy tested to replace frequent eye injections for vision loss
NCT ID NCT07053358
Summary
This early-stage study is testing a single gene therapy injection, called LX111, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal is to see if this one-time treatment is safe and if it can help control the disease, potentially reducing the need for the frequent anti-VEGF eye injections patients currently require. The study will enroll about 10 participants aged 50 and older to monitor their vision and eye health for a year after receiving the injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.